DoD Neurofibromatosis Research Program Anticipated Funding

The FY22 Defense Appropriations Act is anticipated to provide funding to the Department of Defense NFRP to support innovative, high-impact NF research. The managing agent for the anticipated funding opportunities is the Congressionally Directed Medical Research Programs at the U.S. Army Medical Research and Development Command.

The FY22 NFRP funding opportunity announcements for the following award mechanisms will be posted on the website. Pre-application and application deadlines will be available when the announcements are released.

Applications submitted to the FY22 NFRP must address one or more of the following Areas of Emphasis:

  • Neurofibromatosis (NF) Type 2-related areas (e.g., hearing, balance, ependymoma, meningioma)
  • Biomarker discovery, utility, development, and validation
  • Non-tumor manifestations not limited to:
    • Pain
    • Cognitive manifestations
    • Sleep
  • Heterogeneity of NF-related tumors
  • Novel disease and treatment response markers using genetics, genomics, epigenetics, systems biology, metabolomics, or similar approaches
  • Preclinical efficacy studies
  • Target identification, drug discovery
  • Nutritional, environmental, and other modifiers of NF
  • Health services research

Please see the press release for more information. Please reach out to the Office of Sponsored Research and Programs at for help with your proposal.